EnVVeno Medical Corporation (NASDAQ:NVNO) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Headlines Articles Press releases EnVVeno Medical Corporation

Home
Companies
EnVVeno Medical Corporation

BRIEF

published on 08/20/2025 at 13:05, 3 months 15 days ago

EnVVeno Medical Receives Not-Approvable Letter from FDA for VenoValve

EnVVeno Medical VenoValve FDA Decision Deep Venous Disease Premarket Approval
PRESS RELEASE

published on 08/20/2025 at 13:00, 3 months 15 days ago

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)
enVVeno Medical received a not-approvable letter from the FDA for VenoValve, citing lacking hemodynamic data and safety concerns. Company to work on new criteria and potential resubmission

FDA Medical Device EnVVeno Medical VenoValve CVI
BRIEF

published on 08/15/2025 at 15:26, 3 months 20 days ago

EnVVeno Medical to Present at Webull Financial Webinar Series

EnVVeno Medical VenoValve Deep Venous Disease Webull Financial Biotech/MedTech
PRESS RELEASE

published on 08/15/2025 at 15:21, 3 months 20 days ago

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
enVVeno Medical Corporation to present at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 21, 2025, with CEO Robert Berman discussing innovative treatment solutions for deep venous disease

Webinar EnVVeno Medical Corporation Bioprosthetic Solutions Deep Venous Disease Webull Financial
BRIEF

published on 08/06/2025 at 14:35, 3 months 29 days ago

EnVVeno Medical's VenoValve: A Cost-Effective Solution for Severe CVI

FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Healthcare Cost Savings
PRESS RELEASE

published on 08/06/2025 at 14:30, 3 months 29 days ago

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency
Preliminary findings show VenoValve as cost-effective & clinically beneficial for severe CVI. Webcast discussing results. Potential $5.9B annual healthcare savings. Study shows cost savings and clinical benefits

Webcast VenoValve Healthcare Savings CVI Cost-Effectiveness
BRIEF

published on 08/04/2025 at 15:10, 4 months ago

EnVVeno Medical Explores Potential Impact of Trump's CVI Diagnosis on Treatment Options

FDA Approval VenoValve CVI Diagnosis Trump Impact Healthcare Cost
PRESS RELEASE

published on 08/04/2025 at 15:05, 4 months ago

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
enVVeno Medical is developing the VenoValve as a potential treatment for Chronic Venous Insufficiency. FDA decision expected in 2H'2025

EnVVeno Medical VenoValve Chronic Venous Insufficiency FDA Decision Deep Venous Disease
BRIEF

published on 08/01/2025 at 14:05, 4 months 3 days ago

EnVVeno Medical Q2 2025 Financial Report and Corporate Update

EnVVeno Medical VenoValve Q2 2025 Results EnVVe Progress FDA Decision
PRESS RELEASE

published on 08/01/2025 at 14:00, 4 months 3 days ago

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update
enVVeno Medical reports $3.8M cash burn & financial results for Q2 2025. Operations funded through Q3'2026 with sufficient cash. FDA decisions & clinical program progress on track

Financial Results EnVVeno Medical Cash Burn FDA Decisions Clinical Program Progress

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 52 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 57 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 27 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 22 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 27 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 57 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 36 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 2 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 12 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 17 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 27 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 42 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 43 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 26 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE